The transcription factor nuclear factor kappa B (NF-jB) is activated in human breast cancer tissues and cell lines. However, it is unclear whether NF-jB activation is a consequence of tumor formation or a contributor to tumor development. We developed a doxycycline (dox)-inducible mouse model, termed DNMP, to inhibit NF-jB activity specifically within the mammary epithelium during tumor development in the polyoma middle T oncogene (PyVT) mouse mammary tumor model. DNMP females and PyVT littermate controls were treated with dox from 4 to 12 weeks of age. We observed an increase in tumor latency and a decrease in final tumor burden in DNMP mice compared with PyVT controls. A similar effect with treatment from 8 to 12 weeks indicates that outcome is independent of effects on postnatal virgin ductal development. In both cases, DNMP mice were less likely to develop lung metastases than controls. Treatment from 8 to 9 weeks was sufficient to impact primary tumor formation. Inhibition of NF-jB increases apoptosis in hyperplastic stages of tumor development and decreases proliferation at least in part by reducing Cyclin D1 expression. To test the therapeutic potential of NF-jB inhibition, we generated palpable tumors by orthotopic injection of PyVT cells and then treated systemically with the NF-jB inhibitor thymoquinone (TQ). TQ treatment resulted in a reduction in tumor volume and weight as compared with vehicle-treated control. These data indicate that epithelial NF-jB is an active contributor to tumor progression and demonstrate that inhibition of NF-jB could have a significant therapeutic impact even at later stages of mammary tumor progression.
Introduction
To aid discovery of new therapeutics, additional investigation into molecular factors responsible for breast cancer development and progression is required. Nuclear factor kappa B (NF-kB) is a transcriptional regulator of proteins that modulate survival, proliferation, angiogenesis and metastasis (Baud and Karin, 2009) . NF-kB is activated in human breast cancer tissues and cell lines (Nakshatri et al., 1997; Sovak et al., 1997; Biswas et al., 2004) . However, the precise roles played by NF-kB during breast tumor development have not been extensively investigated in vivo. In particular, the role of NF-kB activity specifically within epithelial cells has not been studied. The transcription factor NF-kB is a dimer formed from a multi-subunit family consisting of p65 (Rel A), Rel B, c-Rel, p105/p50 (NF-kB1) and p100/p52 (NF-kB2) (Ghosh et al., 1998; Vallabhapurapu and Karin, 2009 ). Activation of NF-kB is regulated by the binding of inhibitory proteins termed IkBs (Baeuerle and Baltimore, 1988; Hayden and Ghosh, 2008) . In the canonical NF-kB pathway, a dimer composed of the p65 and p50 subunits is held in the cytosol through binding of the inhibitor IkBa. The phosphorylation of IkBa by IkB kinase 2 acts as a signal for the ubiquitination and degradation of the inhibitor. p50/p65 then translocates to the nucleus and binds to the promoter of target genes (Baldwin, 1996; Ghosh et al., 1998; Hayden and Ghosh, 2008) .
Many investigations concerning activation of NF-kB in human breast cancer cells in vitro have focused on a role of NF-kB in providing resistance to chemotherapeutics. Expression of a super repressor of IkBa in MDA-MB-231 cells increases sensitivity to paclitaxelinduced apoptosis (Patel et al., 2000) . Doxorubicin treatment increases NF-kB activity in BT-474 human breast cancer cells and treatment of cells with small interfering RNA against NF-kB subunits p65, p52 and c-Rel leads to a 30-40% increase in doxorubicin toxicity (Tapia et al., 2007) . Although these studies illustrate the potential for inhibition of NF-kB in chemoresistant tumors, they do not determine the role of NF-kB in tumor development.
Few studies have investigated the contribution of NFkB activity to tumor progression in vivo. MDA-MB-231 human breast cancer cells treated with a dominantnegative IkB kinase 2 construct prevented xenograft tumor growth in nude mice (Singh et al., 2007) . A similar reduction in tumor formation was observed in a study wherein NAFA murine mammary tumor cells transfected with a dominant-negative IkBa construct were injected subcutaneously into FVB mice (Liu et al., 2009) . Although these studies suggest that NF-kB may contribute to mammary tumor progression, in both cases cells were injected into areas distinct from the mammary gland such that, the models may not accurately represent the appropriate microenvironment for mammary tumor progression. More importantly, both studies used established tumor cell lines so they do not address the role of NF-kB activity during the early process of cellular transformation. More relevant to this question was a recent study in which a dominant inhibitor of NF-kB, similar to that used here, was targeted directly to the mammary epithelium under the control of the mouse mammary tumor virus (MMTV) promoter and mice subjected to systemic chemical carcinogenesis with the hormone medroxyprogesterone acetate (MPA) and a carcinogen 7,12-dimethylbenzanthracene (DMBA) (Pratt et al., 2009) . Although NF-kB inhibition had no effect on squamous lesions, induction of mammary luminal lesions was reduced.
In this study, we have developed an inducible mouse model that allows us to inhibit NF-kB activity specifically within mammary epithelial cells in vivo as they are transformed and in discrete stages during tumor progression, which we define as the continuum from benign lesion initiated by oncogene expression to malignant tumor. We used the polyoma middle T oncogene (PyVT) transgenic model that effectively represents human mammary tumor development (Lin et al., 2003) . We recently generated a transgenic model in which doxycycline (dox) treatment allows the MMTV-reverse tetracycline transactivator (rtTA) to drive inducible mammary epithelial-specific expression of a mutated form of IkBa that acts a dominant inhibitor of NF-kB activity (Connelly et al., 2010) . In this study, we have combined these models to generate triple transgenics, termed DNMP, in which NF-kB activity can be inhibited by dox treatment in defined windows during PyVT-induced tumorigenesis. Using this new model, we demonstrate that inhibition of NF-kB signaling leads to increased tumor latency and decreased tumor burden. In addition, we demonstrate that significant inhibition of tumor progression can be achieved even after initiation of primary tumor formation. This is mediated by an increase in apoptosis in early stage tumors and an inhibition of proliferation throughout tumor development. In an additional model, we demonstrate that systemic inhibition of NF-kB by thymoquinone (TQ) also inhibits mammary tumor progression. These data show that NF-kB is an active contributor to tumor progression, not merely upregulated as a result of tumor formation, and provide in vivo evidence that inhibition of NF-kB may be an effective therapeutic strategy.
Results
Increased NF-kB activity is associated with mammary tumor development in the PyVT model The PyVT mouse mammary tumor model recapitulates the stages of human disease (Lin et al., 2003) , however, it is not known whether this includes activation of NFkB. Mammary gland nuclear extracts were prepared and western blot performed for the NF-kB p65 subunit as nuclear translocation of p65 indicates NF-kB activation. An increase in nuclear p65 levels was observed in extracts from 7-week-old PyVT mice as compared with control. This increase reached significance in extracts from 12-week-old PyVT (Figure 1a) . We observed phosphorylation of IkBa in orthotopic tumors grown with polyoma mouse mammary tumor cells but not in normal mammary tissue (Figure 1b) . These studies confirmed that NF-kB is activated in PyVT tumors, which represent an appropriate model to investigate effects of inhibiting NF-kB during mammary tumorigenesis.
We developed a modular transgenic mouse model to investigate the effects of inhibiting NF-kB in the mammary epithelium during tumorigenesis. The model combines three transgenes, MMTV-rtTA, (tet-O) 7 -IkBaDN-Myc-His and PyVT, such that treatment of DNMP females with dox induces mammary epithelial expression of the NF-kB inhibitor DN IkBa on the PyVT background. We have previously used this transgene to inhibit NF-kB activity (Connelly et al., 2010) . Littermates lacking the MMTV-rtTA transgene were used as controls (PyVT controls).
Characterization of DNMP mice DNMP mice and PyVT control littermates were treated with dox from 4 to 12 weeks. Mammary glands were harvested and western blots performed on whole-cell extracts to detect expression of the myc-tagged DNIkBa transgene. Expression of the transgene was observed in DNMP mammary glands and was undetectable in PyVT controls (Figure 1c ). Transgene expression was observed in mammary gland but not in the heart, lung, liver, kidney or salivary glands of doxtreated DNMP mice (Figure 1c) . To confirm inhibition, western blot for NF-kB p65 was performed on nuclear extracts from mammary glands of DNMP and PyVT control mice treated with dox from 8 to 9 weeks of age. A significant decrease in nuclear levels of p65 was apparent in DNMP mice compared with PyVT controls (Figure 1d ). This demonstrates that the DN-IkBa transgene is expressed specifically within mammary and functions to inhibit NF-kB activity.
An increase in tumor latency and a reduction in tumor burden is observed in DNMP mice treated with dox from 4 to 12 weeks old DNMP mice and PyVT controls were treated with dox from 4 to 12 weeks of age, that is, encompassing primary tumor development through to metastasis to the lungs. There was a significant increase in tumor latency in DNMP mice as compared with PyVT controls (Figure 2a ). Control mice and DNMP mice developed palpable tumors with a median time of 33 or 43 days from dox administration respectively (Po0.05; control n ¼ 7 and DNMP n ¼ 13). This was accompanied by a reduction in final palpable tumor number ( Figure 2b ) and in mammary tumor burden (Figure 2c ) in DNMP mice on euthanization at 12 weeks old. There was also a reduction in the number of lung metastases with 60% of PyVT controls having surface lung metastases as compared with only 15% of DNMP (Figure 2d ). Thus, inhibition of NF-kB within the mammary epithelium throughout progression to metastasis has a significant impact on tumor burden.
Tumor progression is impacted by inhibition of NF-kB activity in the absence of effects on postnatal development As NF-kB signaling could impact postnatal virgin ductal development, we examined mammary gland Figure 1 Inhibition of NF-kB activity in the PyVT model. (a) Expression of NF-kB p65 in nuclear extracts from 7 and 12-week-old wild-type and PyVT mammary glands. Protein expression was analyzed by western blot of nuclear extracts. Western blot for TATAbinding protein (TBP) was performed as a loading control. Densitometry was performed on western blots and levels normalized to TBP loading control. Data are represented as mean ± s.e. band density. *Po0.05, significantly different from control; n ¼ 3. (b) Expression of phosphorylated IkBa in cytoplasmic extracts from wild-type mammary glands and PyVT (L129) orthotopic tumors. Western blot of IkB and p42/44 MAPK was performed as loading controls. Expression of myc-tagged DN-IkBa transgene in (c) mammary glands (top) or tissues (bottom) from PyVT control and DNMP mice treated with dox (2 g/l from 4 to 12 weeks old). Protein expression was analyzed by western blot of whole-cell extracts. Western blot for actin was performed as a loading control (n ¼ 5). (d) Levels of NF-kB p65 in nuclear extracts from PyVT control and DNMP mammary glands treated with dox (2 g/l from 8 to 9 weeks old). Protein expression was analyzed by western blot of nuclear extracts. Western blot for TBP was performed as a loading control. Densitometry was performed on western blots and levels normalized to TBP loading control. Data are represented as mean±s.e. band density. *Po0.05, significantly different from control; n ¼ 4.
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L Connelly et al whole mounts from DNMP and PyVT controls treated from 4 to 12 weeks with dox. This revealed reduced ductal invasion into the mammary fat pads in DNMP mice suggesting that the transgene may inhibit ductal development ( Figure 3a ). By 8 weeks of age, virgin postnatal development is complete with ductal branching having extended throughout the mammary fat pad. Therefore, DNMP mice and PyVT controls were treated with dox from 8 to 12 weeks. No difference in ductal invasion was observed in DNMP mice versus PyVT control for this treatment time frame (Figure 3a ). Dox treatment from 8 to 12 weeks led to a significant increase in tumor latency in DNMP mice as compared with PyVT controls (Figure 3b ). PyVT controls and DNMP mice developed palpable tumors with a median time of 11 or 16 days from dox administration respectively (Po0.05; control n ¼ 9 and DNMP n ¼ 7). This was again accompanied by a decrease in mammary gland palpable tumor number ( Figure 3c ) and tumor burden ( Figure 3d ). An absence of metastasis was observed with no surface lung tumors found in DNMP mice ( Figure 3e ). These data suggest that the impact of NF-kB inhibition observed on tumor progression is not dependent on developmental effects.
Inhibition of NF-kB signaling leads to increased apoptosis during early stages of tumorigenesis We treated DNMP and PyVT controls with dox from 8 to 9 weeks old to capture a period when signaling changes are occurring that would result in decreases in tumor burden at later stages. Whole-mount analyses from DNMP and PyVT controls treated from 8 to 9 weeks of age demonstrate a dramatic reduction in tumor formation in DNMP mice ( Figure 4a ).
As NF-kB is known to upregulate expression of antiapoptotic proteins (Karin and Ben-Neriah, 2000) , we performed TdT-mediated dUTP nick end labeling (TUNEL) staining to determine whether levels of apoptosis were changed at week 9 after a single week of transgene induction. Analysis of TUNEL staining by tumor stage revealed an increase in apoptosis in hyperplastic lesions in DNMP mice versus PyVT controls (Figure 4b ). Quantification of numbers of macrophages in hyperplastic lesions by immunohistochemistry shows an increase in this population in DNMP mammary compared with controls ( Figure 4c ). It is likely that there is an increased infiltration of macrophages in order to phagocytose the apoptotic cells.
Since we had observed an effect on apoptosis during the early stages of tumorigenesis, but not during later stages, we investigated whether this effect was related to a differential expression of the transgene. We performed immunohistochemistry for myc-tagged transgene expression (Figure 4d ). Analyses in DNMP mammary glands treated with dox from 8 to 9 weeks of age revealed a mosaic pattern of transgene expression. Interestingly, stronger staining was observed in areas of normal tissue and in adenomas than at later stages. The lack of significant effects on apoptosis during early and late carcinoma may be due to the pattern of transgene expression. 
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Inhibition of NF-kB signaling reduces proliferation and Cyclin D1 expression during mammary tumor progression As NF-kB is known to regulate the expression of proteins involved in proliferation (Baud and Karin, 2009) , the effect of DN-IkBa expression on proliferation was investigated in DNMP and PyVT control mammary glands treated with dox from 8 to 9 weeks. Immunohistochemistry and quantification of cells positive for the proliferation-associated antigen Ki67 revealed a significant reduction in proliferation in DNMP mammary (Figure 5a ). To look more specifically at effects on mitosis, sections from DNMP and PyVT control glands from mice treated with dox from 8 to 9 weeks were stained for phospho-histone 3. A significant reduction in phospho-histone 3 was observed in DNMP glands as compared with controls indicating a reduction in cells undergoing mitosis (Figure 5b) . The cell cycle regulatory protein cyclin D1 is a key step in cell cycle progression and is upregulated in human breast cancers (Roy and Thompson, 2006) . Increased expression of cyclin D1 is linked with upregulation of NF-kB activity in the mammary gland (Cao and Karin, 2003) . Western blot for cyclin D1 in mammary glands from mice treated from 8 to 9 weeks old with dox revealed a significant decrease in cyclin D1 protein in DNMP mice (Figure 5c ). These data suggest that NF-kB signaling in the epithelium during tumor progression may regulate cyclin D1 expression as one mechanism to effect proliferation.
NF-kB activity has been linked with promotion of angiogenesis (Liu et al., 2009) . We detected no significant differences between DNMP and PyVT control mammary glands treated with dox from 8 to 9 weeks old in levels of Von Willebrand factor by Treatment with the NF-kB inhibitor TQ inhibits mammary tumor growth Our transgenic model shows that inhibition of NF-kB activity can inhibit mammary tumor progression. To extend the translational potential of our findings, we investigated the impact of systemic NF-kB inhibition on tumor growth. We generated a cell line (PYG129) from a mammary tumor arising in a PyVT transgenic crossed with an NF-kB/luciferase NGL reporter transgenic (Everhart et al., 2006) . These cells were injected via the tail vein into a wild-type recipient and a second cell line (L129) was derived from the metastases that formed in the mouse lung. The plant derivative TQ has been shown to inhibit NF-kB activity and is being investigated as an anticancer treatment (Sethi et al., 2008; Jafri et al., 2010) . We treated L129 cells with 10 ng/ml tumor necrosis factor-a in the presence or absence of 50 mM TQ for 6 h and measured NF-kB activity by luciferase assay. A significant reduction in NF-kB activity was observed in the presence of TQ (Figure 6a ). Orthotopic injection of 1 Â 10 6 L129 cells into the mammary fat pad of wild-type mice led to the formation of a palpable mammary tumor within 10 days. Following detection of a palpable tumor, mice were treated daily by intraperitoneal injection with 40 mg/kg TQ or dimethylsulphoxide vehicle control. TQ-treated tumor volumes were lower as compared with the control group Figure 6b ). This was accompanied by a significant reduction in final tumor weight in TQ-treated mice (Figure 6c) . Similar results were obtained with a second PyVT tumor cell line (data not shown). These data demonstrate that systemic treatment with an NF-kB inhibitor delays tumor expansion.
Discussion
The activation of NF-kB is observed in human breast cancers but whether this transcription factor functionally contributes to disease progression has not been extensively investigated. We have developed a new inducible transgenic mouse model in which NF-kB signaling can be inhibited in the mammary epithelium at specific times during tumor progression in the PyVT mouse mammary tumor model. This allows us to investigate whether NF-kB is an active contributor to tumor development. In initial studies, we examined the effects of NF-kB inhibition from 4 until 12 weeks old encompassing the time period from which primary mammary tumors form to metastasis to the lungs in the PyVT model (Lin et al., 2003) . We observed a significant inhibition of tumor progression. However, our data and other reports suggested that there may be an effect on development of the virgin gland (Brantley et al., 2001; Hennighausen and Robinson, 2005) . To exclude developmental effects from those on tumorigenesis, we inhibited NF-kB from 8 to 12 weeks. Again we observed an increase in tumor latency and a decrease in tumor burden. This suggests that inhibition of NF-kB activity can impact mammary tumor progression independently of effects on development.
In both studies, reduced primary tumor burden was accompanied by a reduced endpoint number of lung metastases. Along with others, we have previously PH3-positive cells were quantified using Metamorph software and expressed as a percentage of total cells, *Po0.05, significantly different from control; n ¼ 6. (c) Expression of cyclin D1 in whole-cell mammary gland extracts. Protein expression was analyzed by western blot. Western blot for actin was performed as a loading control. Densitometry was performed on western blots and levels normalized to actin loading control. Data are represented as mean±s.e. band density. **Po0.05, significantly different from control; n ¼ 4.
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shown that inhibition of NF-kB in the lung epithelium leads to a reduction in lung tumorigenesis (Stathopoulos et al., 2007; Meylan et al., 2009; Basseres et al., 2010) demonstrating that modulation of NF-kB can impact tumor formation in the lung microenvironment. NF-kB modulates expression of genes involved in metastasis, such as matrix metalloproteinases 2 and 9 (Bond et al., 1998; Han et al., 2001) , therefore an effect on metastasis could be predicted. However, as this study demonstrates a significant decrease in primary tumor burden, it is possible that the observed decrease in the number of lung metastases stems from decreased seeding from a smaller primary tumor. We are unable to distinguish putative effects on metastasis from those on primary tumor, thus further investigation will be required to establish a direct effect on lung metastasis. Investigation into the mechanisms responsible for the reduction in primary tumor growth revealed an increase in apoptosis in early stage tumors. This is in agreement with in vitro studies wherein NF-kB inhibition has been shown to promote apoptosis in human breast cancer cells (Singh et al., 2007) . NF-kB activity promotes survival in HeLa cells after mitotic cell cycle arrest is induced by anti-microtubule drugs by blocking apoptosis (Mistry et al., 2004) . Our data indicate that NF-kB may protect hyperplastic cells from apoptosis, allowing them to progress to carcinoma.
Mice in which cyclin D1 expression is driven by the MMTV promoter develop mammary adenocarcinomas suggesting that elevated cyclin D1 contributes to tumor development (Wang et al., 1994) . Cyclin D1 is upregulated in human breast cancers and regulates the transition from G1 to S phase (Fu et al., 2004; Roy and Thompson, 2006) ; therefore, NF-kB may upregulate cyclin D1 and contribute to proliferation. Our model reveals that inhibition of NF-kB signaling leads to a reduction in cyclin D1 accompanied by a decrease in proliferation. We also observed a reduction of phosphorylated histone 3 indicating less cells were undergoing mitosis. Inhibition of NF-kB in HeLa cells has been shown to delay mitotic entry (Cude et al., 2007) , therefore inhibition of NF-kB may impact several stages of cell cycle progression.
In a recent study, a reduction in subcutaneous tumor growth, tumor microvascular density and vascular endothelial growth factor was observed when NAFA murine mammary epithelial cells were stably transfected with a stabilized form of the NF-kB inhibitor IkBa (Liu et al., 2009 ). We did not observe effects on tumor vessel density or the expression of vascular endothelial growth factor (data not shown). One explanation could be the differences between tumors growing in the microenvironment of the mammary gland compared with a subcutaneous tumor.
In a previous study, inhibition of NF-kB signaling with a dominant-negative IKK1 protein did not impact tumor latency or number in the PyVT model but retarded tumor development in the MMTV-c-neu (Erb2/Her2) model (Cao et al., 2007) . NF-kB activity has been linked with HER-2-positive tumors (Biswas and Iglehart, 2006) , therefore further investigation is required in this subtype of tumors. Pratt et al. (2009) targeted mutant IkBa to mammary epithelium using the MMTV promoter. There are significant differences between their studies and this study. They used chemical carcinogen treatment to induce tumor development while this study focused on expression of an oncogenic signal, potentially more closely modeling an inherited genetic mutation. The previous study used constitutive mammary epithelial expression mediated via the MMTV promoter whereas our model is inducible, making feasible investigation of specific temporal windows of intervention. The ability to inhibit NF-kB at later stages during tumor progression allowed us to investigate effects after the stage of postnatal development. The general conclusion from both studies is that inhibition of NF-kB can impact breast tumor progression in a potentially therapeutic manner.
In addition to the experiments performed with the DNMP model, we investigated the effect of systemic treatment with the NF-kB inhibitor TQ on orthotopic mammary tumor progression. These data are in agreement with that of our transgenic model. To the best of our knowledge, this is the first in vivo evidence suggesting that NF-kB inhibition by systemic treatment with TQ has potential for treatment of existing mammary tumors.
This study suggests that NF-kB activity within mammary epithelium contributes to tumor progression in the murine mammary gland. The inhibition of NF-kB decreases primary tumor load and results in decreased numbers of lung metastases. The effect of NF-kB during tumor progression appears to be inhibition of apoptosis and promotion of proliferation via cyclin D1 signaling. These results are relevant to current efforts aimed at developing inhibitors of NF-kB for treatment of cancer (Baud and Karin, 2009) . They demonstrate that inhibition of NF-kB in vivo during primary mammary gland tumor development can be effective in blocking primary tumor progression with consequent effects on the extent of metastasis to the lung. The observation that inhibition of NF-kB signaling for a single week significantly decreases tumor load in a time frame in which primary tumors have already developed as a result of a strong oncogenic stimulus is particularly interesting. As this models the clinical situation in which a patient is likely to present, we provide evidence that inhibition of NF-kB may prove to be an effective therapeutic strategy for treating patients with an existing breast tumor.
Materials and methods

Isolation of PYG/L129 cells
Mammary tumors from PyVT mice crossed with NGL reporter mice (Everhart et al., 2006) on the FVB background were minced and washed with Dulbecco's modified Eagle's medium containing fungizone (Invitrogen, Carlsbad, CA, USA) and gentamicin (Invitrogen). Tumor pieces were plated in Dulbecco's modified Eagle's medium with 10% fetal bovine serum plus antibiotics and incubated at 37 1C in 5% CO 2 until tumor cells covered the dish. Single colonies were isolated and expanded. In all, 1 Â 10 6 cells were injected into the tail vein of an FVB mouse. After 6 weeks, lungs were harvested and a single tumor dissected out and L129 cells derived as above.
In all, 0.5 Â 10 6 cells per well were plated in six-well plates and incubated for 24 h. Cells were treated with 10 ng/ml tumor necrosis factor-a (Pierce Biotechnology, Rockford, IL, USA) in the presence or absence of 50 mM TQ (MP Biomedicals, LLC, Solon, OH, USA) for 6 h. For TQ plus tumor necrosis factor-a treatment, cells were pretreated for 1 h with TQ, medium removed and replaced with TQ plus tumor necrosis factor-a for the 6-h treatment. Medium was removed and cells were washed with phosphate-buffered saline before addition of Lysis Buffer (Promega, Madison, WI, USA). The extracts were then centrifuged (13 793 Â g, 4 1C, 5 min) and supernatants retained. Luciferase activity was measured as described (Connelly et al., 2007) .
Mouse models
All animal experiments were approved by the Vanderbilt University Institutional Animal Care and Use Committee. All mice were on an FVB strain background. MMTV-rtTA mice (Gunther et al., 2002) were crossed with the PyVT mouse mammary tumor model. MMTV-rtTA/PyVT mice were crossed with mice containing the NF-kB inhibiting (tet-O) 7 -IkB-aDN-Myc-His construct Connelly et al., 2010) to obtain mice carrying all three transgenes, these were termed DNMP. Littermates carrying the PyVT and DNIkBa transgenes but lacking the MMTV-rtTA transgene were used as controls. DNMP mice (and controls) were treated with 2g/l freshly prepared dox (Sigma-Aldrich, St Louis, MO, USA) in drinking water from 4 to 12 weeks, 8 to 12 weeks or 8 to 9 weeks old. Sucrose (5%) was added to decrease the bitter taste of dox water. A red bottle was used to prevent light-induced dox degradation and water was replaced twice weekly. DNMP mice (and controls) treated with dox from 4 to 12 weeks or 8 to 12 weeks were palpated twice weekly from 7 weeks of age to check for tumor formation. Tumor latency was determined as the day a tumor was first palpated from the start of dox treatment. At the time of euthanization, palpable tumors were counted and mammary glands weighed to determine total gland mass (g).
Orthotopic injection of L129 cells and TQ treatment
Female FVB mice were injected in the right #4 inguinal mammary fat pad with 1 Â 10 6 L129 cells in phosphatebuffered saline. Daily intraperitoneal injections of TQ (40 mg/ kg) in dimethylsulphoxide or vehicle control were begun at day 10 after injection of cells when tumors were approximately 150 mm 3 . On every second day tumor volume was measured with calipers. Body weight of each mouse was measured daily, no toxicity was observed. At euthanization, tumors were weighed to determine mass (g).
Quantification of lung metastases
Lungs of mice treated from 4 to 12 weeks or 8 to 12 weeks of age with dox were inflated at the time of euthanization with Bouin's fixative. Surface tumors were counted by two blinded readers under a dissecting microscope and counts averaged.
Whole-mount analyses
Number 4 inguinal mammary glands of dox-treated mice were collected, prepared and imaged as previously described (Connelly et al., 2007) .
Immunohistochemistry and immunofluorescence
Number 4 inguinal mammary glands of mice dox treated from 8 to 9 weeks of age were fixed in 10% formalin overnight at 4 1C. Glands were then dehydrated in a graded ethanol series followed by xylenes and embedded in paraffin. In all, 5 mm sections were prepared and stained for Ki67 expression (Vanderbilt University Medical Center Immunohistochemistry Core Laboratory). For Ki67 quantification, 10 images were captured per slide at Â 63 magnification using a Zeiss Axioplan 2 microscope (Thornwood, NY, USA) and total Ki67-positive cells and total nuclei per field were counted by two blinded readers. Additional 5 mm sections were assessed for apoptosis using the Deadend Fluorometric TUNEL system (Promega). Staining was performed utilizing rabbit antiphospho-histone 3 primary antibody (Upstate-Millipore, Danvers, MA, USA) along with goat anti-rabbit Alexa Fluor 488 conjugated secondary antibody (Invitrogen), rat anti-F4/ 80 primary antibody (Invitrogen) along with goat anti-rat fluorescein isothiocyanate-conjugated secondary antibody (AbD Serotec, Raleigh, NC, USA) and mouse anti-c-myc primary antibody (Sigma-Aldrich) along with goat anti-mouse Alexa Fluor 594 conjugated secondary antibody (Invitrogen). Slides were counterstained using 4,6-diamidino-2-phenylindole (Sigma-Aldrich). For TUNEL quantification, three images from each of the four different stages of tumor progression were captured per slide using a Zeiss Axioplan 2 microscope at Â 20 magnification. Tumor stage was assessed using the criteria described by Lin et al. (2003) . For F4/80 quantification, three images of hyperplastic lesions per section were captured at Â 40 magnification. For phospho-histone 3 quantification, three images of tumor area per section were captured at Â 20 magnification. Total nuclei (4,6-diamidino-2-phenylindole) and TUNEL, phospho-histone 3 and F4/80-positive cells were separately counted using Metamorph software (Molecular Devices, Sunnyvale, CA, USA) and the average of the three images calculated.
Western blotting
Whole-cell mammary gland extracts and nuclear extracts were prepared and western blot performed as previously described (Connelly et al., 2010) . Primary antibodies: cyclin D1, p42/44 MAPK, IkB and IkBa (Cell Signaling Technology, Danvers, MA, USA), p65 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), TATA-binding protein (Santa Cruz Biotechnology), Myc-tag (Sigma-Aldrich) and actin (Santa Cruz Biotechnology).
Statistical analyses
Statistical analyses were performed using Graph Pad Prism (GraphPad Software Inc., San Diego, CA, USA). Densitometric analyses were performed using Odyssey V3.0 software (Licor, Lincoln, NE, USA). All data are plotted graphically with vertical bars representing s.e. A Student's t-test or MannWhitney test was used to assess differences between experimental conditions. Significance of data represented in the Kaplan-Meier curves was determined using log-rank (MantelCox) and Gehan-Breslow-Wilcoxon tests for statistical significance. For statistical analyses a probability (P) value of o0.05 was taken as an appropriate level of significance.
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